Case Study of COVID-19 Vaccine-Associated Myocarditis
Published: 2022-07-29
Page: 102-109
Issue: 2022 - Volume 5 [Issue 1]
Fahad Alharbi
King Abdulaziz Hospital, MNGHA, Al Ahsa, Saudi Arabia.
Muneera AlTaweel *
King Abdulaziz Hospital, MNGHA, Al Ahsa, Saudi Arabia and Echocardiography Technologist, King Abdulaziz Hospital, MNGHA Al Ahsa, Saudi Arabia.
Sarah AlMukhaylid
College of Applied Medical Sciences (CoAMS-A), King Saud Bin Abdulaziz University for Health, Saudi Arabia.
Rana Faqeehi
King Abdullah International Medical Research Center (KAIMRC), Al Ahsa, Saudi Arabia.
Tarek Nasef
King Abdulaziz Hospital, MNGHA, Al Ahsa, Saudi Arabia.
*Author to whom correspondence should be addressed.
Abstract
COVID-19 mRNA vaccines have serious side effects, including myocarditis; it’s an uncommon but dangerous side effect following mRNA-based COVID-19 immunization. Herein we report a 45-year-old female presenting with myocarditis seven days after the second dose of Pfizer-BioNTech vaccine, yet to recover three months later with guideline-directed medical treatment. COVID-19-associated myocarditis was evaluated and treated similarly to typical myocarditis with reduced ejection fraction heart failure, after exhausting other possible different etiologies. Here we illustrate various causes of myocarditis, contrasting diagnostic approaches, prognosis, and solidating management guidelines.
Keywords: COVID-19 vaccine, COVID-19 induced myocarditis, COVID-19